Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice GuidelineJulie R. Brahmer, John A. Thompson, Jennifer S. Mammen et al.|Journal of Clinical Oncology|2018Cited by 3.7k
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working GroupMarc S. Ernstoff|Journal for ImmunoTherapy of Cancer|2017Cited by 2k
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse eventsJulie R. Brahmer, Marc S. Ernstoff|Journal for ImmunoTherapy of Cancer|2021Cited by 804
Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic MelanomaPaul B. Chapman, John M. Kirkwood, Lawrence H. Einhorn et al.|Journal of Clinical Oncology|1999Cited by 763
Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged SkinF. Stephen Hodi, David E. Fisher, Christopher L. Corless et al.|Journal of Clinical Oncology|2013Cited by 594